Other Events ·
Precision BioSciences, Inc. reported clinical highlights from its ELIMINATE-B study for chronic hepatitis B, showing a…
DTILPrecision Biosciences Inc
Precision BioSciences, Inc. reported clinical highlights from its ELIMINATE-B study for chronic hepatitis B, showing a 1-log reduction in cccDNA-derived transcripts via PBGENE-HBV. The company also announced the activation of a second clinical site at Washington University School of Medicine for its FUNCTION-DMD clinical trial. Precision BioSciences, Inc. is a biotechnology company focused on developing gene editing technologies for therapeutic use.